OxyVita is a molecule that is specifically designed with the purpose of delivering Oxygen to the human (or animal) body.
The basic principles of our science: Blood transfusions are not as safe as we would want them to be. When an individual goes into the Hospital and needs a transfusion, the list of warnings is close to a paragraph long! Also, Whole blood isn’t always available for use, be it because of lack of inventory (let’s not forget that blood relies on donations) or a lack of specific blood type in inventory, or even location (remote areas and ambulances cannot have blood stored).
The world has been on a quest to solve the problem of the blood transfusion. The reliance on blood is staggering, and while many of us live in places where delivery of blood is not a problem, like heavily populated areas, there is a very significant portion of the population that do not have easy access. When considering the picture of the whole world, the problem only grows in magnitudes. In 2006, and alarming statistic from Mexico was published where there were 25 million transfusions that were needed, that went un-performed.
And we are not alone. The animals that we call pets also have a need for blood transfusions as a mode of treatment in veterinary offices. What’s troubling is that there is a lack of a centralized blood banking body, like the Red Cross for humans, in the animal market-place.
OxyVita is a stand alone product, based on an ubiquitous source, cleaned, manufactured and packaged in a production laboratory. The product, which is considered an equivalent to a red blood cell transfusion, has none of the short-comings of the red blood cell transfusion. The product has no blood type, does not carry disease, and has an incredible storage shelf life. What’s more, the scientists at OXYVITA have been able to make a powder form of the product – stable at room temperature for up to 5 years!
This is a product that looks like red blood cells, is administered like red blood cells, with an amazing curbing of risk associated. The product may be one day used not only in the hospital, since there is no typing or storage restriction, it could be used in ambulances, battlefields and perhaps even on site!
OxyVita has undergone years of animal model testing, and is currently in the process of studies to approach the veterinary marketplace. It is expected that our furry friends will have access to the life-saving potential of this product within the next 12-24 months. Humans will have to continue to wait for the time being, but a product for human use is also being prepared.
OXYVITA has been working with the Naval Medical Research Center (NMRC) in Bethesda, MD over the past several years in testing the potential for the OxyVita product to be used in Traumatic Brain Injury (TBI) treatment. It is theorized that because of the smaller size of the molecule, as well as the increased oxygen carrying capacity, that the OxyVita product may be able to minmize damage caused to brain tissue in TBI situations. TBI is an extremely detrimental condition, caused primarily by head injury, that many of the soldiers over-seas suffer. The results from the last several years have prompted the Navy to move forward with the study, and sign a new Collaborative Research and Development Agreement (CRADA), with the aim of moving forward with the studies, eventually testing in large animal models. OXYVITA is very excited to have this strong and capable partner behind the use of the product and as a collaborator in the field.
Professor Harrington of OXYVITA submitted a chapter for publication to a blood substitute specific textbook. As of February 2014, Springer publishing has published this textbook. The text-book is titled Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics.
Furthermore, OxyVita is mentioned more than once through out the textbook. This gives a third party verification of the promise that the OxyVita product line offers!
Dr. Hanna Wollocko, President and CEO of OXYVITA Inc. was interviewed as the honored guest on September 10th episode of the polish news show “Polonia 24″.
The interview surrounded the OxyVita product and the need for the product world-wide. Dr. Wollocko presented the product and our unique tecnology. This opportunity allowed OXYVITA to be introduced as a leader in the oxygen therapeutic market throughout the world, while demonstrating the intent to enter the European marketplace. OXYVITA is currently exploring opportunities in the overseas markets. The news cast is broadcast throughout the world, with primary viewership in populations of Polish descent.
Dr. Hanna Wollocko, President and CEO of OXYVITA Inc. was invited to participate as a panel speaker at the 2012 Economic Forum in Krynica. Dr. Wollocko presented the OxyVita products and their impact on medicine in emergency treatement.
The benefit of having this type of treatment mode, as presented by Dr. Wollocko, was two fold. First, by bringing treatment to patients at the site of the accident. OxyVita’s unique properties allow for it to be potentially carried on ambulances, for administration at the site of the accident, thereby potentially avoiding the patient succumbing to a shock situation. Secondly, there is a great financial benefit to the use of OxyVita product. Not only does it potentially eliminate overhead costs of blood administration, but also can reduce the cost of treatment by keeping the patient out of shock, and therefore reducing the cost of care for the patient in the overall scenario. The participation in this forum has demonstrated that the OxyVita product is a serious proponent and candidate for approval and use in the global market. The European Union has taken notice of the unique characteristics. The participation in this forum has opened doors for OXYVITA in the European Marketplace. The presence of the pharmaceutical sector was not significant at the conference. OXYVITA and J&J were two amongst a few with a significant showing at the forum.